BioSpecifics Technologies Corp. (NASDAQ:BSTC) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Boasting a price of $45.17, BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded -4.80% lower on the day. With the last close up 9.49% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. BioSpecifics Technologies Corp. has recorded a 50-day average of $41.87 and a two hundred day average of $38.80. Volume of trade was down over the average, with 48,928 shares of BSTC changing hands under the typical 55,740
Zacks Investment Research has downgraded BioSpecifics Technologies Corp. (NASDAQ:BSTC) to Hold in a statement released on 10/11/2016.
On 7/16/2015, MLV & Co released a statement on BioSpecifics Technologies Corp. (NASDAQ:BSTC) bumped up the target price from $0.00 to $76.00 that suggested an upside of 0%.
With a total market value of $0, BioSpecifics Technologies Corp. has price-earnings ratio of 28.53 with a one year low of $30.70 and a one year high of $63.20 .
A total of 1 analyst has released a research note on BSTC. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $76.00.
More About BioSpecifics Technologies Corp. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren's contracture and Peyronie's disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren's contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.